Fundraising FoxAmplo Biotechnology
Pompano Beach, US · Founded 2019 · Delaware corporation · 1 known investors
Find your way into Amplo Biotechnology
Sign up to see every warm intro you have to Amplo Biotechnology
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Amplo Biotechnology team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Amplo Biotechnology develops adeno-associated virus (AAV) gene therapies for genetic diseases of the neuromuscular junction, targeting rare and ultra-rare patient populations such as those with Congenital Myasthenic Syndromes. Its work focuses on delivering proteins like Dok-7 and Collagen Q that are essential to neuromuscular junction function.
Founders & leadership
AH
Al HawkinsPresident / Program Director
JK
Jean KimNamed on SEC filing
PH
Paul HawkinsNamed on SEC filing
TV
Terry VanceNamed on SEC filing
MP
Matthew PaulsNamed on SEC filing
Board
Investors · 1
BioBritlisted by BioBritLa Jolla
How we know: a partner's Signal profile · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$2.2M disclosed across 1 round · 2021
▶$2.2MraisedOct 2021 · 15 investors · BiotechnologyRule 506(b)
▶$2.2MraisedOct 2021 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jean KimDirector
- Paul HawkinsExecutive Officer, Director
- Terry VanceDirector
- Daniel BradburyDirector
- Matthew PaulsDirector
- Patricio SepulvedaExecutive Officer, Director
- Offering amount
- $2.5M
- Amount sold
- $2.2M
- First sale
- Sep 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 6
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Aro BiotherapeuticsAro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.
Cerecor Inc.Avalo is a clinical-stage biotechnology company developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases. Its pipeline includes abdakibart (AVTX-009), tested in a Phase 2 trial for hidradenitis suppurativa, and AVTX-010, a long-acting next-generation anti-IL-1β antibody.
Applied TherapeuticsApplied Therapeutics is a biopharmaceutical company developing novel drugs for rare diseases with high unmet medical need. Its Aldose Reductase Inhibitor franchise is in development across disease areas including Galactosemia and SORD Deficiency.
Artelo BiosciencesArtelo Biosciences develops therapeutic treatments by modifying lipid signaling pathways to treat cancer and other serious conditions at the clinical stage.
ArpelosArpelos Biosciences is a seed-stage biotech company developing multivalent targeted therapeutics aimed at high potency and selectivity, drawing on compute, immunology, and protein engineering. It is based in Kendall Square (Cambridge, Massachusetts).
Companies working in the same space as Amplo Biotechnology.
Frequently asked questions
- What does Amplo Biotechnology do?
- Amplo Biotechnology develops adeno-associated virus (AAV) gene therapies for genetic diseases of the neuromuscular junction, targeting rare and ultra-rare patient populations such as those with Congenital Myasthenic Syndromes. Its work focuses on delivering proteins like Dok-7 and Collagen Q that are essential to neuromuscular junction function.
- Who are Amplo Biotechnology's investors?
- Amplo Biotechnology's investors include BioBrit.
- How much funding has Amplo Biotechnology raised?
- Amplo Biotechnology has disclosed $2.2M raised across 1 round.
- Where is Amplo Biotechnology headquartered?
- Amplo Biotechnology is headquartered in Pompano Beach, US.